Improving rate of decline of FEV1 in young adults with cystic fibrosis

Thorax

Volumn 61, Issue 2, 2006, Pages 155-157

  Que, C ^a   Cullinan, P ^a   Geddes, D ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; FORCED EXPIRATORY VOLUME; GRAM NEGATIVE INFECTION; HUMAN; LUNG FIBROSIS; LUNG FUNCTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PSEUDOMONAS; STATISTICAL ANALYSIS;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; BODY HEIGHT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CYSTIC FIBROSIS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; VITAL CAPACITY;

EID: 32544448208     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.2005.043372     Document Type: Article

References (20)

1. Milla CE, Warwick WJ. Risk of death in cystic fibrosis patients with severely compromised lung function. Chest 1998;113:1230-4.
2. Rosenbluth DB, Wilson K, Ferkol T, et al. Lung function decline in cystic fibrosis patients and timing for lung transplantation referral. Chest 2004;126:412-9.
3. Augarten A, Akons H, Aviram M, et al. Prediction of mortality and timing of referral for lung transplantation in cystic Fibrosis patients. Pediatr Transplant 2001;5:339-42.
4. Davis PB, Byard PJ, Konstan MW. Identifying treatments that halt progression of pulmonary disease in cystic fibrosis. Pediatr Res 1997;41:161-5.
5. Konstan MW, Byard PJ, Hoppel CL, et al. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995;332:848-54.
6. Ramsey BW, Dorkin ML, Eisenberg JD, et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993;328:1740-6.
7. Corey M, Levison H, Crozier D. Five- to seven-year course of pulmonary function in cystic fibrosis. Am Rev Respir Dis 1976;114:1085-92.
8. Kerem E, Corey M, Gold R, et al. Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa. J Pediatr 1990;116:714-9.
9. Kovesi T, Corey M, Levison H. Passive smoking and lung function in cystic fibrosis. Am Rev Respir Dis 1993;148:1266-71.
10. Eigen H, Rosenstein B, FitzSimmons S, et al. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. J Pediatr 1995;126:515-23.
11. Corey M, Edwards L, Levison H, et al. Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis. J Pediatr 1997;131:809-14.
12. Milla CE, Warwick WJ, Moran A. Trends in pulmonary function in patients with cystic fibrosis correlate with the degree or glucose intolerance at baseline. Am J Respir Crit Care Med 2000;162:891-5.
13. Merkus PJ, Tiddens HA, de Jongste JC. Annual lung function changes in young patients with chronic lung disease. Eur Respir J 2002;19:886-91.
14. Merkus PJ, Govaere ES, Hop WH, et al. Preserved diffusion capacity in children with cystic fibrosis. Pediatr Pulmonol 2004;37:56-60.
15. Rosenbluth DB, Wilson K, Ferkol T, et al. Lung function decline in cystic fibrosis patients and timing for lung transplantation referral. Chest 2004;126:412-9.
16. Augarten A, Akons H, Aviram M, et al. Prediction of mortality and timing of referral for lung transplantation in cystic fibrosis patients. Pediatr Transplant 2001;5:339-42.
17. Schaedel C, De Monestrol I, Hjelte L, et al. Predictors of deterioration of lung function in cystic fibrosis. Pediatr Pulmonol 2002;33:483-91.
18. Kosorok MR, Zeng L, West SE, et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol 2001;32:277-87.
19. Xu W, Subbarao P, Corey M. Changing patterns of lung function decline in children with cystic fibrosis. J Cystic Fibrosis 2004;3:S116.
20. Hodson ME, Koch C, Harries HK, et al. The European Epidemiologic Registry of Cystic Fibrosis (ERCF). Does dornase alfa make any difference? In: Proceedings of the 22nd European CF Conference, Berlin, Germany. Berlin: European CF Conference, 1998:66.